Details for Patent: 9,572,803

Which drugs does patent 9,572,803 protect, and when does it expire?

Patent 9,572,803 protects VANTRELA ER and is included in one NDA.

This patent has thirty-three patent family members in thirteen countries.

Summary for Patent: 9,572,803

Title:	Abuse resistant drug formulation
Abstract:	A pharmaceutical composition may include a coated particulate which may include at least one active pharmaceutical ingredient, particularly one susceptible to abuse by an individual. The coated particles may include a fat/wax and have improved controlled release and/or crush resistance. Method of making these coated particulate and dosage forms therewith are also described.
Inventor(s):	Habib; Walid A. (Maple Grove, MN), Hamed; Ehab (Maple Grove, MN), Vega Zepeda; Manuel A. (Minneapolis, MN)
Assignee:	Cima Labs Inc. (Brooklyn Park, MN)
Application Number:	13/728,801
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 9,572,803

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Teva Branded Pharm	VANTRELA ER	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	207975-001	Jan 17, 2017		DISCN	Yes	No			Y
Teva Branded Pharm	VANTRELA ER	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	207975-002	Jan 17, 2017		DISCN	Yes	No			Y
Teva Branded Pharm	VANTRELA ER	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	207975-003	Jan 17, 2017		DISCN	Yes	No			Y
Teva Branded Pharm	VANTRELA ER	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	207975-004	Jan 17, 2017		DISCN	Yes	No			Y
Teva Branded Pharm	VANTRELA ER	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	207975-005	Jan 17, 2017		DISCN	Yes	No			Y

International Family Members for US Patent 9,572,803

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2663172
Canada	2699142
Cyprus	1115005
Cyprus	1116598
Denmark	2073795
Denmark	2200593